Prodrive Technologies’ Post

🔍📚 Check out our latest publication! 📊✨ The paper "An intelligent hybrid ensemble model for early detection of breast cancer in multidisciplinary healthcare systems" has been published in the journal Diagnostics and had the contribution of the SaLLy • Statistical Learning Laboratory members Hasnain Iftikhar, Paulo Canas Rodrigues, and Javier Linkolk! Access the full paper here: https://lnkd.in/dxxHBCzu. 🎉🌟 #SaLLy

ASCO 2026 is approaching — and together with Cornelia Leo, Prof. Dr., FEBS and José L. Sandoval, we are already deep into our OncoPulse Switzerland briefing discussions. A wealth of new breast cancer data will be presented in Chicago this year, and our goal is clear: to identify, prioritize, and discuss the abstracts that are most relevant for Swiss clinical practice. Over the coming days, we will share the key abstracts selected to look at and potentially discuss with you in our closed expert group “OncoPulse Switzerland”. https://lnkd.in/eu8bZw48 Stay tuned — exciting weeks ahead. #OncoPulseSwitzerland #ASCO #SwissPerspective #CongressIntelligenceForSwitzerland #endresprojects

At Scifiniti Publishing, we are committed to advancing impactful scholarly publishing that shapes the future. We are proud to highlight ”Covalent BH3-Mimetics and PROTACs Targeting BCL2 Family for Precision Apoptosis Induction”, a publication published in Targeted Cancer Therapy Connect Vol.1. Promoting academic excellence through high-quality research communication. 🔗Read more: https://lnkd.in/dHPZNGS8 Author: Abinash Nayak #ScifinitiPublishing #TargetedTherapy #CancerResearch #DrugDevelopment #MolecularOncology #PrecisionMedicine

Proud to spotlight this publication in Targeted Cancer Therapy Connect, highlighting innovative approaches in precision apoptosis induction and targeted cancer therapy. Explore the article: https://lnkd.in/dHPZNGS8 #ScifinitiPublishing #TargetedCancerTherapyConnect #CancerResearch #DrugDevelopment #PrecisionMedicine #MolecularOncology

Advancing research in low-grade intermediate-risk non-muscle-invasive bladder cancer (#NMIBC) depends on the collaboration of patients, families, and clinical research teams. We’re grateful to John A. Taylor, III, MD, MS, and the exceptional team at the University of Kansas Medical Center for partnering with us to support participants in the #SURF302 trial and their critical role in moving #bladdercancer research forward. Learn more about the study: https://surf302.bio/ #TyraBiosciences

🤔 How does IGF-1 help #ProstateCancer cells evade the immune system? Let's unpack the exciting #research findings observed by Professor Val Macaulay and Professor Ian Mills, from the Nuffield Department of Surgical Sciences - University of Oxford, in a paper published in Scientific Reports (part of the Nature Portfolio). 📘 You can read the full paper here: https://lnkd.in/edAMf64c This paper was warmly dedicated to the memory of Val, who sadly passed away before its publication. Val is a greatly missed member of the Prostate Cancer UK research community.

Formal Press Release: Support for Prostate Cancer Research In Saskatchewan "This partnership represents an important step toward addressing the unique challenges faced by men with prostate cancer in Saskatchewan," said Murray Hill, chair of the Prostate Cancer Support Group–Saskatoon, and Dr. Kishor M. Wasan, board director and chair of the scientific advisory committee at PCFC. "By investing in locally led research through SHRF, we are supporting solutions that can make a meaningful difference in patient outcomes and care experiences." https://lnkd.in/gpRv4Tb8 #PCFC #ProstateCancer #Research #Awareness #Support #Education

almost 28 years of work - but I think we now know why some DCIS will progress and others do not. It's all about immunity.

An interview with my mentor Dr. Polyak on our discovery of Treg progenitors shaping the immune escaped ecosystem within the breast microlesions and invasive breast cancer. Very grateful that we have the resilience and strength to push this important piece of work to the finish line! Dana-Farber Cancer Institute

This is exciting work! No doubt far too many people choose aggressive management of DCIS due to fear it will return or progress. Patients & HCP's need more information to make decisions.